• Medical Professionals
    • Information for Healthcare Providers
    • Clinical Studies
    • Expanded Access
    • Educational Grants
    • Request Information
  • Press releases
  • Suppliers
  • Contact
  • Skip to main content
  • Skip to footer

Atara Biotherapeutics

  • About
    • Company
    • Management Team
    • Board of Directors
    • Collaborators
    • Contact
  • Technology
  • Pipeline
    • Atara Pipeline
    • Tab-cel
    • ATA188
    • ATA2271/ATA3271
    • ATA3219
  • Patients
    • Mission to Serve Patients
    • Clinical Studies
    • Expanded Access
    • Request Information
    • PTLD Champions
    • Multiple Sclerosis
  • Investors & Media
    • Investors & Media
    • News & Events
    • Financial Results
    • ATRA Stock
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Careers
    • Join Our Team
    • Life at Atara
    • Explore Career Opportunities
    • Tech Ops
    • Job Search
  • Medical Professionals
  • Suppliers
  • Press Releases
  • Contact
  • LinkedIn
  • Twitter
Investors & Media

Investors & Media

  • Investors & Media
  • News & Events
    • Overview
    • Press Releases
    • Events
    • Presentations
    • Email Alerts
    • Investor & Media Contacts
  • Financial Results
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • ATRA Stock
    • Quote
    • Charts
    • Historical Data
    • FAQ
    • Classification Info
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Contact The Board
  • News
  • Careers

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • Events
  • Presentations
  • Email Alerts
  • Investor & Media Contacts

Atara Biotherapeutics Appoints Pascal Touchon President, Chief Executive Officer and Member of the Board of Directors

May 28, 2019 5:00pm EDT

Atara Biotherapeutics Announces Presentations Highlighting Tab-celĀ® and Mesothelin-Targeted CAR T Clinical Results at American Society of Clinical Oncology (ASCO) Annual Meeting

May 15, 2019 5:05pm EDT

Atara Biotherapeutics Announces Presentation of Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN)

May 15, 2019 8:30am EDT

Atara Biotherapeutics Announces First Quarter 2019 Financial Results and Recent Operational Progress

May 09, 2019 8:00am EDT

Atara Biotherapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019

May 07, 2019 4:41pm EDT

Atara Biotherapeutics Presents Off-the-Shelf, Allogeneic CAR T Preclinical Results at the American Association of Cancer Research (AACR) Annual Meeting 2019

Apr 01, 2019 4:10pm EDT

Atara Biotherapeutics Announces Collaborator Presentation of Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma

Mar 31, 2019 11:00am EDT

Atara Biotherapeutics to Participate in Upcoming Conferences

Mar 07, 2019 9:00am EST

Atara Biotherapeutics Announces Presentations Highlighting Next-Generation CAR T Platform and Mesothelin-Targeted CAR T Clinical Results at American Association of Cancer Research (AACR) Annual Meeting 2019

Feb 27, 2019 5:20pm EST

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Progress

Feb 26, 2019 7:30am EST
RSS
  • Prev
    • 1...
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • ...22
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed

    Footer

    • LinkedIn linkedin
    • Twitter twitter
    © 2021 Atara Biotherapeutics, Inc. All Rights Reserved
    • Privacy Policy
    • Sitemap

    This website uses cookies and similar technologies to optimise and improve the experience on our site. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy


    OK